In 2018, the RCO released new guidelines on screening for hydroxychloroquine and chloroquine retinopathy. This was in response to an increase in the use of the drugs, drugs that for a long time have been known to have significant ocular side effects. The new guidelines make specific recommendations on the techniques and timing of baseline and follow-up screening tests. To understand the importance of these drugs, dermatologist Dr Sharon Blackford provides a background summary on their clinical use. Following this, ophthalmologist Dr Tariq Aslam explains the new guidelines and how they will work in practice.